Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs
Cancer science, 2022-07, Vol.113 (7), p.2224-2231 [Peer Reviewed Journal]2022 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. ;2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. ;2022. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1347-9032 ;EISSN: 1349-7006 ;DOI: 10.1111/cas.15377 ;PMID: 35445479
Full text available